788081-99-2

Basic information

• Product Name: 2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER
• Synonyms: 2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER;Methyl 2-(broMoMethyl)-5-Methoxybenzoate;Benzoic acid, 2-(bromomethyl)-5-methoxy-, methyl ester
• CAS NO: 788081-99-2
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.11
• Mol File: 788081-99-2.mol

Chemical Properties

• Boiling Point: 342.5°C at 760 mmHg
• Flash Point: 160.9°C
• Appearance: /
• Density: 1.432g/cm³
• Vapor Pressure: 7.52E-05mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER(788081-99-2)
• EPA Substance Registry System: 2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER(788081-99-2)

Safety Data

• Hazardous Substances Data: 788081-99-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER is used as a building block in the synthesis of various organic compounds for the development of pharmaceutical drugs. Its unique structure allows for the creation of new molecules with potential therapeutic properties.
Used in Chemical Synthesis:
2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER is used as an intermediate in the production of various chemical compounds, contributing to the synthesis of specialty chemicals or materials with specific properties.
Used in Research and Development:
2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER is utilized in research and development for exploring its potential applications and properties. It may serve as a starting material for the discovery of new chemical reactions or as a model compound for studying the effects of its functional groups on chemical behavior.
Used in Agrochemicals Production:
2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER may be used as an intermediate in the production of agrochemicals, such as pesticides or herbicides, due to its potential biological activity and ability to be modified for specific applications in agriculture.
Used in Specialty Chemicals Manufacturing:
2-BROMOMETHYL-5-METHOXY-BENZOIC ACID METHYL ESTER has potential industrial uses in the manufacturing of specialty chemicals or materials, where its unique structure and properties can be leveraged to create products with specific characteristics or functions.

InChI:InChI=1/C10H11BrO3/c1-13-8-4-3-7(6-11)9(5-8)10(12)14-2/h3-5H,6H2,1-2H3

Upstream product

• 67-56-1 methanol 
• 3168-59-0 5-methoxy-o-toluic acid 
• 35450-36-3 methyl 2-bromo-5-methoxybenzoate 
• 578-22-3 2-methyl-5-hydroxybenzoic acid 
• 2840-04-2 5-amino-2-methylbenzoic acid 
• 1975-52-6 5-nitro-o-toluic acid 
• 73502-03-1 methyl 5-methoxy-2-methyl-benzoate 

Downstream Products

• 944718-10-9 2-Bromomethyl-6-methoxy-2,3-dihydro-isoindol-1-one 
• 944718-09-6 2,2-Dimethyl-propionic acid 6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl ester 
• 113811-62-4 5-methoxy-2-<(phenylsulfonyl)methyl>benzaldehyde 
• 659737-57-2 6-hydroxy-2,3-dihydro-1H-isoindol-1-one 

Relevant articles and documents

Br?nsted Acid Catalyzed Dearomatization by Intramolecular Hydroalkoxylation/Claisen Rearrangement: Diastereo- and Enantioselective Synthesis of Spirolactams

Described herein is a novel Br?nsted acid catalyzed intramolecular hydroalkoxylation/Claisen rearrangement, allowing the practical and atom-economic synthesis of a range of valuable spirolactams from readily available ynamides in generally good to excellent yields with excellent diastereoselectivities and broad substrate scope. Importantly, an unexpected dearomatization of nonactivated arenes and heteroaromatic compounds is involved in this tandem sequence. Moreover, an asymmetric version of this tandem cyclization was also achieved by efficient kinetic resolution by chiral phosphoric acid catalysis. In addition, the [3,3]-rearrangement is shown to be kinetically preferred over the related [1,3]-rearrangement by theoretical calculations.

Palladium-Catalyzed Tandem Carbonylative Diels-Alder Reaction for Construction of Bridged Polycyclic Skeletons

A palladium-catalyzed tandem carbonylative lactonization and Diels-Alder cycloaddition reaction between aldehyde-tethered benzylhalides and alkenes has been developed. A range of alkenes and aldehyde-tethered benzylhalides bearing different substituents can be successfully transformed into the corresponding bridged polycyclic compounds in good yields. This strategy provides a unique approach to complex lactone-containing bridged polycyclic compounds.

Copper-promoted direct amidation of isoindolinone scaffolds by sodium persulfate

Isoindolinones are ubiquitous structural motifs in natural products and pharmaceuticals. Establishing an efficient method for structural modification of isoindolinones could significantly facilitate new drug development. Herein, we describe copper-promoted direct amidation of isoindolinone scaffolds mediated by sodium persulfate. The method exhibits mild reaction conditions and high site-selectivity, and enables the structural modification of the drug indobufen ester with various amides with yields of 49 to 98%. It is also gram-scalable. Additionally, the reaction mechanism appears to involve a radical and a carbocationic pathway.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, T

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

Assessment of the regioselectivity in the condensation reaction of unsymmetrical o-phthaldialdehydes with alanine

One approach for the synthesis of isoindolinones, a privileged bioactive heterocyclic core structure, involves a condensation reaction of o-phthaldialdehydes with a suitable nitrogen-containing nucleophile. This fascinating reaction is revisited here in the context of the use of o-phthaldialdehydes that contain additional substituents in the aromatic ring leading to a detailed analysis of the regioselectivity of the reaction. Eleven monosubstituted o-phthaldialdehydes were synthesised and reacted with alanine. The regioselectivity observed across the eleven substrates led to the design of a disubstituted substrate that reacted with very high control. A gram-scale reaction followed by esterification gave one major regioisomer in high yield. In addition, the regioselectivity observed on reaction of two novel monodeuterated substrates led to an increased mechanistic understanding.

Development of Novel Inhibitors for Histone Methyltransferase SET7/9 based on Cyproheptadine

The histone methyltransferase SET7/9 methylates not only histone but also non-histone proteins as substrates, and therefore, SET7/9 inhibitors are considered candidates for the treatment of diseases. Previously, our group identified cyproheptadine, used clinically as a serotonin receptor antagonist and histamine receptor (H1) antagonist, as a novel scaffold of the SET7/9 inhibitor. In this work, we focused on dibenzosuberene as a substructure of cyproheptadine and synthesized derivatives with various functional groups. Among them, the compound bearing a 2-hydroxy group showed the most potent activity. On the other hand, a 3-hydroxy group or another hydrophilic functional group such as acetamide decreased the activity. Structural analysis clarified a rationale for the improved potency only by tightly restricted location and type of the hydrophilic group. In addition, a SET7/9 loop, which was only partially visible in the complex with cyproheptadine, became more clearly visible in the complex with 2-hydroxycyproheptadine. These results are expected to be helpful for further structure-based development of SET7/9 inhibitors.

Metabolically stable dibenzo[ b, e ]oxepin-11(6 H)-ones as highly selective p38 MAP kinase inhibitors: Optimizing anti-cytokine activity in human whole blood

Five series of metabolically stable disubstituted dibenzo[b,e]oxepin-11(6H) -ones were synthesized and tested in a p38α enzyme assay for their inhibition of tumor necrosis factor-α (TNF-α) release in human whole blood. Compared to the monosubstituted dibenzo[b,e]oxepin-11(6H)-one derivatives, it has been shown that the additional introduction of hydrophilic residues at position 9 leads to a substantial improvement of the inhibitory potency and metabolic stability. Using protein X-ray crystallography, the binding mode of the disubstituted dibenzoxepinones and the induction of a glyince flip in the hinge region were confirmed. The most potent compound of this series, 32e, shows an outstanding biological activity on isolated p38α, with an IC50 value of 1.6 nM, extraordinary selectivity (by a factor >1000, Kinase WholePanelProfiler), and low ATP competitiveness. The ability to inhibit the release of TNF-α from human whole blood was optimized down to an IC50 value of 125 nM. With the promising dibenzoxepinone inhibitor 3i, a pharmacokinetic study in mice was conducted.

Biaryl substituted hydantoin compounds as TACE inhibitors

We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors. SAR with respect to the non-prime region of TACE active site was explored. A series of biaryl substituted hydantoin compounds was shown to have sub-nanomolar Ki